REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
28/03/2026
Voltar para busca
Dado oficial do USPTO
IPSEN BIOPHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
IPSEN BIOPHARMACEUTICALS
ST13
US500000085519918Classe
5
Pedido
85519918
Registro
5171734
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
101
Atualização mais recente
29/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
19/01/2012
Data de registro
28/03/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/08/2023
Última transação
29/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
701
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
16/04/2012
Primeiro uso no comércio
16/04/2012
Código do desenho
4
Tipo de titular
99
Localização do titular
Paris, FR
Examinador
DINALLO, KEVIN M
Unidade examinadora
L70
Localização atual
TMEG LAW OFFICE 107
Titulares e representantes
Titulares
IPSEN S.A.
IPSEN S.A.
Representantes
Ben Natter HAUG PARTNERS, LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, and for cardiovascular and cognitive disorders; pharmaceutical preparations for use in urology, pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations for the treatment and prevention of neuromuscular disorders; pharmaceutical preparations for the treatment and prevention of cervical dystonia, cerebral palsy, and spasticity
Publicações
Histórico de despachos e eventos da marca no USPTO.
101 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/08/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/08/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/08/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
29/08/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
29/08/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
23/08/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
23/08/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/08/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/08/2023
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
17/08/2023
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
17/08/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
17/08/2023
ES8R
TEAS SECTION 8 RECEIVED
16/03/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
28/03/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
14/01/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/01/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
14/01/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/01/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/01/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
14/01/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/01/2022
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
06/01/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
06/01/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/01/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/01/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
30/12/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
30/12/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
30/12/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
30/12/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
30/12/2021
CORV
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
18/06/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
15/05/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
15/05/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
15/05/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/05/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/05/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
15/05/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
28/03/2017
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
24/02/2017
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
23/02/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
23/02/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
23/02/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
23/02/2017
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
23/02/2017
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
26/08/2016
GNFR
FINAL REFUSAL E-MAILED
26/08/2016
CNFR
SU - FINAL REFUSAL - WRITTEN
26/08/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/07/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/07/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/07/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/01/2016
GNRT
NON-FINAL ACTION E-MAILED
08/01/2016
CNRT
SU - NON-FINAL ACTION - WRITTEN
08/01/2016
SUPC
STATEMENT OF USE PROCESSING COMPLETE
15/12/2015
IUAF
USE AMENDMENT FILED
10/12/2015
EISU
TEAS STATEMENT OF USE RECEIVED
10/12/2015
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
16/06/2015
EX5G
SOU EXTENSION 5 GRANTED
13/06/2015
EXT5
SOU EXTENSION 5 FILED
28/05/2015
EEXT
SOU TEAS EXTENSION RECEIVED
28/05/2015
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/12/2014
EX4G
SOU EXTENSION 4 GRANTED
01/12/2014
EXT4
SOU EXTENSION 4 FILED
24/11/2014
EEXT
SOU TEAS EXTENSION RECEIVED
24/11/2014
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
23/05/2014
EX3G
SOU EXTENSION 3 GRANTED
22/05/2014
EXT3
SOU EXTENSION 3 FILED
15/05/2014
EEXT
SOU TEAS EXTENSION RECEIVED
15/05/2014
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
17/12/2013
EX2G
SOU EXTENSION 2 GRANTED
16/12/2013
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/12/2013
EXT2
SOU EXTENSION 2 FILED
22/10/2013
EEXT
SOU TEAS EXTENSION RECEIVED
22/10/2013
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/06/2013
EX1G
SOU EXTENSION 1 GRANTED
03/06/2013
EXT1
SOU EXTENSION 1 FILED
03/06/2013
EEXT
SOU TEAS EXTENSION RECEIVED
03/06/2013
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/12/2012
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/10/2012
PUBO
PUBLISHED FOR OPPOSITION
16/10/2012
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/09/2012
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/09/2012
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/09/2012
XAEC
EXAMINER'S AMENDMENT ENTERED
10/09/2012
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/09/2012
GNEA
EXAMINERS AMENDMENT E-MAILED
10/09/2012
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/09/2012
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
07/09/2012
GPRA
PRIORITY ACTION E-MAILED
07/09/2012
CPRA
PRIORITY ACTION WRITTEN
07/09/2012
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/08/2012
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/08/2012
ALIE
ASSIGNED TO LIE
03/08/2012
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/08/2012
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
27/04/2012
GPRA
PRIORITY ACTION E-MAILED
27/04/2012
CPRA
PRIORITY ACTION WRITTEN
27/04/2012
DOCK
ASSIGNED TO EXAMINER
26/04/2012
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/01/2012
NWAP
NEW APPLICATION ENTERED
23/01/2012
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IPSEN BIOPHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.